anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Geriatric patients are at increased risk for developing severe tendon disorders including tendon rupture when being treated with a fluoroquinolone such as levofloxacin. This risk is further increased in patients receiving concomitant corticosteroid therapy. Tendinitis or tendon rupture can involve the Achilles, hand, shoulder, or other tendon sites and can occur during or after completion of therapy; cases occurring up to several months after fluoroquinolone treatment have been reported. Caution should be used when prescribing levofloxacin to elderly patients especially those on corticosteroids. Patients should be informed of this potential side effect and advised to discontinue levofloxacin and contact their healthcare provider if any symptoms of tendinitis or tendon rupture occur [see Boxed Warning; Warnings and Precautions ( 5.2); and Adverse Reactions ( 6.3)].    
In Phase 3 clinical trials, 1,945 levofloxacin-treated patients (26%) were ≥ 65 years of age. Of these, 1,081 patients (14%) were between the ages of 65 and 74 and 864 patients (12%) were 75 years or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.   
Severe, and sometimes fatal, cases of hepatotoxicity have been reported post-marketing in association with levofloxacin. The majority of fatal hepatotoxicity reports occurred in patients 65 years of age or older and most were not associated with hypersensitivity. Levofloxacin should be discontinued immediately if the patient develops signs and symptoms of hepatitis [see Warnings and Precautions ( 5.8)].   
Epidemiologic studies report an increased rate of aortic aneurysm and dissection within two months following use of fluoroquinolones, particularly in elderly patients [see Warnings and Precautions ( 5.9)].    
Elderly patients may be more susceptible to drug-associated effects on the QT interval. Therefore, precaution should be taken when using levofloxacin with concomitant drugs that can result in prolongation of the QT interval (e.g., Class IA or Class III antiarrhythmics) or in patients with risk factors for torsade de pointes (e.g., known QT prolongation, uncorrected hypokalemia) [see Warnings and Precautions ( 5.11)].    
The pharmacokinetic properties of levofloxacin in younger adults and elderly adults do not differ significantly when creatinine clearance is taken into consideration. However, since the drug is known to be substantially excreted by the kidney, the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Clinical Pharmacology ( 12.3)].
BACKGROUND: Anomalous aortic origin of a coronary artery from the inappropriate sinus of Valsalva (AAOCA) is a rare congenital heart lesion. It is uncommon for patients with AAOCA to present with severe symptoms at a very young age.
CASE PRESENTATION: We describe a very rare but critical presentation in a young infant with AAOCA that requires surgical repair and pacemaker placement. A three-month-old infant was referred because of syncope. Cardiac arrest occurred shortly after admission. The electrocardiogram indicated a complete atrioventricular block and a transvenous temporary pacemaker was implanted. A further coronary computed tomographic angiography (CTA) showed the anomalous origin of the right coronary artery from the left sinus of Valsalva. Coronary artery unroofing was performed due to an interarterial course with the intramural component, and a permanent epicardial pacemaker was implanted. The postoperative recovery was uneventful, and this patient was thriving and asymptomatic at the nine-month follow-up. However, the electrocardiogram still indicated a complete pacing rhythm.
CONCLUSIONS: By timely diagnosis and treatment, this patient is successfully rescued. Although rare, AAOCA may be fatal even in infants.
Sildenafil will be given an one time dose 30 to 90 minutes prior to cardiac catheterization. Sildenafil will be given at a dose 1 milligram per kilogram with a maximum of 20 milligrams. During the catheterization patients will have specialized catheter placed in the heart that measures pressure and volume simultaneously. The patients will undergo an infusion of dobutamine up to 10 micrograms per kilogram per minute to mimic exercise for up to ten minutes..
Experimental group 1 got this intervention containing Gong's mobilization for 15-20 mins, followed by conventional physiotherapy treatment (hot pack).Participants were treated 3 times per week for 4 weeks. Pre and Post treatment readings were taken in 1st session and 4th week respectively. Assessment was done via Numeric pain rating scale, neck disability index, universal goniometer and modified sphygmomanometer test.
The invention relates to an application of zirconium compounds in toothpaste, and zirconium-containing toothpaste. The toothpaste is characterized in that: the zirconium compounds comprise zirconium dioxide, zirconium carbonate and zirconium hydroxide. The zirconium compounds are used for completely or partially replacing an abrasive and a sterilizing and odor removing agent in the toothpaste. The zirconium compounds bring no irritation, allergic reaction or side-effect to gingiva and teeth. The zirconium compounds are safe and clean, and have a good mouthfeel. The toothpaste prepared by using the method provided by the invention brings highly efficient and mild cleaning effect, excellent whitening effect and good odor removing effect to teeth. The application scope of the toothpaste is wide.
Memory deficits in Alzheimer's disease (AD) show a strong link with GABAergic interneuron dysfunctions.1,2,3,4,5,6,7 The ensemble dynamics of GABAergic interneurons represent memory encoding and retrieval,8,9,10,11,12 but how GABAergic interneuron dysfunction affects inhibitory ensemble dynamics in AD is unknown. As the retrosplenial cortex (RSC) is critical for episodic memory13,14,15,16 and is affected by β-amyloid accumulation in early AD,17,18,19,20,21 we address this question by performing Ca2+ imaging in RSC parvalbumin (PV)-expressing interneurons during a contextual fear memory task in healthy control mice and the 5XFAD mouse model of AD. We found that populations of PV interneurons responsive to aversive electric foot shocks during contextual fear conditioning (shock-responsive) significantly decreased in the 5XFAD mice, indicating dysfunctions in the recruitment of memory-encoding PV interneurons. In the control mice, ensemble activities of shock-responsive PV interneurons were selectively upregulated during the freezing epoch of the contextual fear memory retrieval, manifested by synaptic potentiation of PV interneuron-mediated inhibition. However, such changes in ensemble dynamics during memory retrieval and synaptic plasticity were both absent in the 5XFAD mice. Optogenetic silencing of PV interneurons during contextual fear conditioning in the control mice mimicked the memory deficits in the 5XFAD mice, while optogenetic activation of PV interneurons in the 5XFAD mice restored memory retrieval. These results demonstrate the critical roles of contextual fear memory-encoding PV interneurons for memory retrieval. Furthermore, synaptic dysfunction of PV interneurons may disrupt the recruitment of PV interneurons and their ensemble dynamics underlying contextual fear memory retrieval, subsequently leading to memory deficits in AD.
Safety and effectiveness of escitalopram has not been established in pediatric patients (less than 12 years of age) with Major Depressive Disorder. 

Information related to usage of escitalopram in adolescents is approved for Forest Laboratories, Inc.'s Escitalopram Oxalate Tablets and Oral Solution. However, due to Forest Laboratories, Inc.'s marketing exclusivity rights, this drug product is not labeled with that adolescent usage information.

Safety and effectiveness of escitalopram has not been established in pediatric patients less than 18 years of age with Generalized Anxiety Disorder. 

Decrease appetite and weight loss have been observed in association with the use of SSRIs. Consequently, regular monitoring of weight and growth should be performed in children and adolescents treated with an SSRI such as escitalopram.
This paper presents a model to externally induce deformation of a fibre introduced inside a human lung. The fibre contains ferromagnetic materials and has a cross-section of 0.4x0.22 µm and length of 20 µm. The fibre heating is achieved by applying an external high frequency magnetic field (2.6kA/m, 1.0MHz) to induce eddy currents in the ferromagnetic materials. Prediction of the thermal bending of the fibre requires multi physics modeling. A finite element model is constructed to calculate the electromagnetic energy dissipation within the fibre. The deposited energy is coupled to a heat-transfer model to calculate the temperature rise. The distribution of temperature inside the fibre then allows prediction of fibre deformation. A 2.2 µm tip displacement is achieved in the solid mechanic analysis. This is the first attempt to use thermal heating induced by a high frequency oscillatory magnetic field to cause deformation of a foreign fibre in the human body.      PACS: 46.70.Hg; 41.20.Gz; 62.20.Fe; 87.80.Rb Keywords: Fibre deformation, eddy current, lung, ferromagnetic material
JAK2V617F is the most recurrent genetic mutation in Philadelphia-negative chronic Myeloproliferative Neoplasms (MPNs). Since the JAK2 locus is located on Chromosome 9, we hypothesized that Chromosome 9 copy number abnormalities may be a disease modifier in JAK2V617F-mutant MPN patients. In this study, we identified a subset of MPN patients with partial or complete Chromosome 9 trisomy (+9p patients), who differ from JAK2V617F-homozygous MPN patients as they carry three JAK2 alleles as well as three copies of all neighboring gene loci, including CD274, encoding immunosuppressive Programmed death-ligand 1 (PD-L1) protein. Investigation of the clonal hierarchy revealed that the JAK2V617F occurs first, followed by +9p. Functionally, CD34+ cells from +9p MPN patients demonstrated increased clonogenicity, generating a greater number of primitive colonies, due to high OCT4 and NANOG expression, with knock-down of these genes leading to a genotype-specific decrease in colony numbers. Moreover, our analysis revealed increased PD-L1 surface expression in malignant monocytes from +9p patients, while analysis of the T cell compartment unveiled elevated levels of exhausted cytotoxic T cells. Overall, here we identify a distinct novel subgroup of MPN patients, who feature a synergistic interplay between +9p and JAK2V617F that shapes immune escape characteristics and increased stemness in CD34+ cells.
Patients receive tremelimumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients also receive durvalumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients achieving disease control may restart treatment upon evidence of progressive disease, with or without confirmation.
PURPOSE:To obtain a cosmetic base effective in protecting the skin, hair, etc., from external physical force and usable to a wide variety of cosmetics by cationizing pullulan at a desired average substitution degree and compounding the obtained cationized pullulan. CONSTITUTION:The cosmetic contains a cationized pullulan produced by reacting pullulan with one or more kinds of cationizing agents selected from the compounds of formula I (R1 to R3 are hydrocarbon group; X is halogen) and formula II (Y is halogen). The obtained cationized pullulan is e.g. the compound of formula III (R4 is H or group of formula IV; n is 20-20,000). Hair cosmetic such as shampoo compounded with the cationized pullulan has excellent adhesiveness to the hair to impart springiness and stiffness to the hair and exhibits excellent conditioning effect. A cosmetic compounded with the cationized pullulan gives excellent smoothness and moistness to the skin over a long period and exhibits properties suitable as a cream or lotion. It can be used as a cosmetic required to have the transparency and clearness of a liquid-type cosmetic.
The process of human parturition involves inflammation at the interface where fetal chorion trophoblast cells interact with maternal decidual stromal (DS) cells and maternal immune cells in the decidua (endometrium of pregnancy). This study tested the hypothesis that inflammation at the chorion-decidua interface (CDI) induces labor by negating the capacity for progesterone (P4) to block labor and that this is mediated by inactivation of P4 in DS cells by aldo-keto reductase family 1 member C1 (AKR1C1). In human, Rhesus macaque, and mouse CDI, AKR1C1 expression increased in association with term and preterm labor. In a human DS cell line and in explant cultures of term human fetal membranes containing the CDI, the prolabor inflammatory cytokine, interleukin-1ß (IL-1ß), and media conditioned by LPS-stimulated macrophages increased AKR1C1 expression and coordinately reduced nuclear P4 levels and P4 responsiveness. Loss of P4 responsiveness was overcome by inhibition of AKR1C1 activity, inhibition of AKR1C1 expression, and bypassing AKR1C1 activity with a P4 analog that is not metabolized by AKR1C1. Increased P4 activity in response to AKR1C1 inhibition was prevented by the P4 receptor antagonist RU486. Pharmacologic inhibition of AKR1C1 activity prevented parturition in a mouse model of inflammation-induced preterm parturition. The data suggest that inflammatory stimuli at the CDI drive labor by inducing AKR1C1-mediated P4 inactivation in DS cells and that inhibiting and/or bypassing of AKR1C1-mediated P4 inactivation is a plausible therapeutic strategy to mitigate the risk of inflammation-associated preterm birth.
Subjects perform the variation of the TNTA task for active CT. After the Learning Phase, sham neuromodulation is performed using the same montage of the active tDCS. However, the electric current fade in during 15 seconds until reaching 2 mA, then is constant at 2 mA for 15 seconds and fade out for 15 seconds. There is no current for the rest of the time.
The recommended initial dose is 4 mg (two capsules) followed by 2 mg (one capsule) after each unformed stool until diarrhea is controlled, after which the dosage of loperamide hydrochloride capsules should be reduced to meet individual requirements. When the optimal daily dosage has been established, this amount may then be administered as a single dose or in divided doses.

The average daily maintenance dosage in clinical trials was 4 to 8 mg (two to four capsules). A dosage of 16 mg (eight capsules) was rarely exceeded. If clinical improvement is not observed after treatment with 16 mg per day for at least 10 days, symptoms are unlikely to be controlled by further administration. Loperamide hydrochloride capsules administration may be continued if diarrhea cannot be adequately controlled with diet or specific treatment.
1. If the woman has not adhered to the prescribed regimen (Haloette has been out of the vagina for more than three hours or the preceding ring-free interval was extended beyond one week), consider the possibility of pregnancy at the time of the first missed period and discontinue Haloette use if pregnancy is confirmed. 
  2. If the woman has adhered to the prescribed regimen and misses two consecutive periods, rule out pregnancy. 
  3. If the woman has retained one Haloette for longer than four weeks, rule out pregnancy.
Systems, methods, and computer-readable media for optimizing a clinical experience are provided. Individuals may be approved by a patient to receive notifications of clinical events. The notifications may be accessed from the patient's electronic health record. In embodiments, a location of a clinician associated with a patient and a location of the patient are received. A determination whether the clinician is near the patient is made. Upon determining that the clinician is near the patient, a notification is sent to a non-present party (e.g., a family member) via a mobile device. Such notifications include individuals in the clinical process and avoid missed opportunities for interactions with clinicians.
The invention discloses long non-coding RNA (ribonucleic acid) related with endometrial cancer, as well as siRNA (short interfering ribonucleic acid) and application thereof. The total length of cDNA (complementary deoxyribonucleic acid) of a gene is 1867bp, and the sequence is as shown in SEQ. ID. NO. 3. After the specific sequence is obtained, the sequence of the siRNA is designed for transfection; after a fragment is adopted for knocking down the expression of molecules of the long non-coding RNA in HEC-1-B cells, the proliferative activity of tumor cells is found to be lowered. Thus, the function of the gene can be related with the proliferation capability of cancer cells. After the interfering fragment siRNA1535 is adopted for knocking down the expression level of the gene, the proliferative activity of the tumor cells is obviously reduced, and the long non-coding RNA can be further applied to preparation of anti-tumor medicaments.
The invention discloses a preparation method and application of a pig interleukin 17 and 22 co-expression alternate biological preparation. The invention provides a fusion protein, which comprises pig interleukin 17 and pig interleukin 22. Specifically, the protein is shown as a sequence 1 or a sequence 3. Nucleic acid molecules encoding proteins are also within the scope of the invention. Expression cassettes, recombinant vectors, transfected cells or recombinant microorganisms having the nucleic acid molecules are within the scope of the invention. The invention also protects the culture product of the transfected cell or the fermentation product of the recombinant microorganism. The invention also protects the application of the biological material: preparing a product for improving the animal immunity; improving the animal immunity; preparing a vaccine; against infection by pathogenic microorganisms; the biological material is the protein or the nucleic acid molecule or the expression cassette or the recombinant vector or the transfected cell or the recombinant microorganism or the culture product or the fermentation product.
The invention relates to a preparation method of Yujin aerosol and new application. The invention is made of the effective compositions of extract and volatile oil extracted from houttuynia cordata and honeysuckle. The invention also discloses the preparation method and new medical application of the Yujin aerosol. The houttuynia dordata and the honeysuckle are extracted and processed into the aerosol. The aerosol has direct effect on an afflicted part and respond to treatment is quick. The efficiency of medicine can be ensured, meanwhile, the adverse effect of injection can be overcome. The aerosol of the invention is not only convenient for use but applicable to other diseases such as gynecological inflammation and has good curative effect.
This clinical trial evaluated the effect of sonic activation of a desensitizing gel on the occurrence of sensitivity associated with office bleaching. For this, 31 patients had their anterior superior teeth divided into right and left, according to the sonic activation (AS) or not (SS) of the desensitizer. Prior to bleaching, a desensitizing gel containing 5% potassium nitrate and 2% sodium fluoride (Desensibilize KF2%, FGM Dental Products,SC, Brazil) was applied. Sonic activation was performed with a sonic device (Smart, FGM Dental Products, SC, Brazil) at the 170 MHz frequency. A hydrogen peroxide gel (Whiteness HP Maxx, FGM Dental Products, SC, Brazil) was used in two whitening sessions. It was also performed, evaluation of the presence of cracks in enamel, through transillumination. The color change was verified using two color scales and a spectrophotometer. The dental sensitivity was recorded through a sensitivity diary answered by the patient, in the period up to 48 hours after each bleaching session. The absolute risk of tooth sensitivity was compared using the McNemar test (= 5%). The color change was analyzed from the variation of units of scale vita (SGU) and through the value of ΔE, which were compared through Student t test (α = 5%).
Subjects were treated only once. Specifically, this consisted in the application of a square wave biphasic electrical current, with 10 Hz frequency, a 250µs pulse width, and the maximal tolerable intensity to cause an exacerbated muscle contraction for a total of 1.5 mins, according to the protocol (Valera \& Minaya). The subjects were lying prone in decubitus. The middle part of the sciatic nerve was located using an ultrasound machine (cross section), then an acupuncture needle (0.30 mm x 40 mm) was inserted in a short axis approach, perpendicular to the surface of the skin, to the perineurium of the sciatic nerve.
The standard of care plus arm will include audit and feedback of blood pressure control rates at the provider level along with web-based training about: 1) barriers to blood pressure and cardiovascular disease (CVD) risk factors management in at-risk patient populations; 2) strategies to address healthcare disparities in clinical settings; and 3) appropriate blood pressure (BP) measurement techniques for all clinical staff. The Hopkins research team will help clinics develop audit and feedback mechanisms if they are lacking and will provide all blood pressure measurement and web-based training.
Objective.Equivalent uniform aerobic dose (EUAD) is proposed for comparison of integrated cell survival in tumors with different distributions of hypoxia and radiation dose.Approach.The EUAD assumes that for any non-uniform distributions of radiation dose and oxygen enhancement ratio (OER) within a tumor, there is a uniform distribution of radiation dose under hypothetical aerobic conditions with OER = 1 that produces equal integrated survival of clonogenic cells. This definition of EUAD has several advantages. First, the EUAD allows one to compare survival of clonogenic cells in tumors with intra-tumor and inter-tumor variation of radio sensitivity due to hypoxia because the cell survival is recomputed under the same benchmark oxygen level (OER = 1). Second, the EUAD for homogeneously oxygenated tumors is equal to the concept of equivalent uniform dose.Main results. We computed the EUAD using radiotherapy dose and the OER derived from the18F-Fluoromisonidazole PET (18F-FMISO PET) images of hypoxia in patients with glioblastoma, the most common and aggressive type of primary malignant brain tumor. The18F-FMISO PET images include a distribution of SUV (Standardized Uptake Value); therefore, the SUV is converted to partial oxygen pressure (pO2) and then to the OER. The prognostic value of EUAD in radiotherapy for hypoxic tumors is demonstrated using correlation between EUAD and overall survival (OS) in radiotherapy for glioblastoma. The correction to the EUAD for the absolute hypoxic volume that traceable to the tumor control probability improves the correlation with OS.Significance. While the analysis proposed in this research is based on the18F-FMISO PET images for glioblastoma, the EUAD is a universal radiobiological concept and is not associated with any specific cancer or any specific PET or MRI biomarker of hypoxia. Therefore, this research can be generalized to other cancers, for example stage III lung cancer, and to other hypoxia biomarkers.
Intervention: Open or laparoscopic hernia repair with mesh (non-absorbable or partly-absorbable alloplastic material) or with direct suture repair. For hernias measuring ≥ 3 cm mesh repair is recommended. A wide overlap of the mesh over the fascia margin on each side has to be provided. Divergent types of repair are permitted but have to be documented.
Ivabradine, 7,5 mg b.id. by mouth for 14-16 weeks.